The AVPC-m consisting of combined defects in any two of the three tumor suppressors TP53, RB1 and PTEN has been linked to distinct clinicopathological features, a poor prognosis, androgen indifference and platinum sensitivity in advanced prostate cancers [1,2,5]. Here, TP53 is linked to prostate cancer.